will rise 10.30%, while the growth in revenue is estimated to hit 24.10% for the next quarter. The rating firms predict current quarter revenue for Fate Therapeutics Inc. Moreover, analysts have looked to higher expectations by upgrading its fiscal year 2023 revenue estimates. ET by Tomi Kilgore Fate Therapeutics upgraded to outperform from neutral at Wedbush, price. As can be gleaned from the statistics, the company’s share value shot -66.70% over the past 6 months, a 31.27% in annual growth rate that is considerably higher than the industry average of 10.40%. Fate Therapeutics stock price target cut to 75 from 125 at Truist Apr. share is performing relatively much better than most of its peers within the same industry. (FATE) estimates and forecastsĭata shows that the Fate Therapeutics Inc. To hit the forecast high, the stock’s price needs a -152.37% plunge from its current level, while the stock would need to tank 36.91% for it to hit the projected low. According to analyst projections, FATE’s forecast low is $4.00 with $16.00 as the target high. The consensus price target for the stock as assigned by Wall Street analysts is $8.32, meaning bulls need an upside of 23.8% from its current market value.
Fate Therapeutics Inc.’s EPS for the current quarter is expected to be -$0.61. Of the remaining, 15 recommended FATE as a Hold, 6 felt it is a Buy and 1 rated the stock as Underweight. If we narrow down to specifics, the data shows that 1 out of 24 analysts rate the stock as a Sell, with a further 1 assigning it an Overweight rating. (FATE) stock a consensus recommendation rating of a Hold, calculated at a mean rating of 2.60. The lowest target is 4.00 and the highest is 28. The company’s 5Y monthly beta was ticking 1.48. According to 16 stock analysts, the average 12-month stock price forecast for FATE stock stock is 8.56, which predicts an increase of 50.70. A look at the daily price movement shows that the last close reads 6.00, with intraday deals fluctuated between 5.985 and 6.225. Reflecting more-speculative story stocks, ARK Innovation ETF ( ARKK ) slumped 4.5 last week and ARK Genomics ETF ( ARKG ) 5.3. When we look at Fate Therapeutics Inc.’s average trading volume, we note the 10-day average is 3.04 million shares, with the 3-month average coming to 2.80 million.Īnalysts gave the Fate Therapeutics Inc. (NASDAQ:FATE) price closed higher on Friday, April 21, jumping 3.67 above its previous close. AMD stock is a major SMH holding with ON stock also in the ETF. The share price had its 52-week low at $4.02, which suggests the last value was 36.59% up since then.
FATE’s last price was a discount, traded about -485.65% off its 52-week high of $37.13. With the company’s per share price at $6.34 changed hands at $0.12 or 1.93% during last session, the market valuation stood at $600.33M. (NASDAQ:FATE) shares changed hands as the company’s beta touched 1.49. In the last trading session, 1.43 million Fate Therapeutics Inc.
0 kommentar(er)
